FILTER
FILTERED INTERVIEW RESULTS
Michael Kauffman
CEO, KARYOPHARM THERAPEUTICS
GBR speaks to Karyopharm Therapeutics about the commercialization of XPOVIO.
Eric Ostertag M.D., Ph.D.
CEO, POSEIDA THERAPEUTICS
Poseida Therapeutics explains how progress in gene therapy offers the possibility to provide single treatment cures for cancer and other genetic diseases.
Amit Munshi
PRESIDENT & CEO, ARENA PHARMACEUTICALS
Arena Pharmaceuticals speaks to GBR about building its pipeline and infrastructure.
Dr. Andrea Pfeifer
CO-FOUNDER & CEO, AC IMMUNE
AC Immune describes its research into neurodegenerative diseases.
Mark Egerton
CEO, QUOTIENT SCIENCES
Quotient Sciences is a drug development and manufacturing accelerator that supports pharmaceutical and biotech companies with services spanning the entire development pathway from candidate selection to commercial launch.
Jay Shukla
PRESIDENT & CEO, NIVAGEN PHARMACEUTICALS, INC.
Nivagen Pharmaceuticals provides complete research, analytical formulation development, and regulatory support.
Dr. Jagadeesh Babu Rangisetty
FOUNDER & CEO, BIOPHORE
Biophore explains how it is expanding productions of different APIs to ensure both quality and supply chain security.
James Gale
CEO, SIGNET HEALTHCARE PARTNERS
Signet Healthcare Partners speaks to GBR about how it is evolving its’ investment portfolio in life sciences.
Emer Leahy
PRESIDENT AND CEO, PSYCHOGENICS
PsychoGenics explains how CNS is attracting unprecedented attention and how its AI-driven phenotypic discovery platforms can help to deliver cures.
Keith Crandell
CO-FOUNDER & MANAGING DIRECTOR, ARCH VENTURE PARTNERS
ARCH Venture Partners explains the secrets to successful innovation in todays’ life sciences.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
Chile Mining 2025
After navigating years of uncertainty and challenges, Chile’s mining industry has returned to peak performance.
After navigating years of uncertainty and challenges, Chile’s mining industry has returned to peak performance.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
